Amyris, Inc., a vertically integrated biomanufacturing company based in Emeryville, California, has announced that it will acquire Oobli Inc., a Davis, California-based developer of fermentation-derived sweet proteins. The acquisition is expected to close in the coming weeks.
The transaction brings together Amyris' scientific capabilities and manufacturing depth with Oobli's protein fermentation expertise. Amyris said the move follows its expansion of manufacturing capacity earlier this year at its fermentation facility in Barra Bonita, Brazil, and represents a strategic commercial and technology expansion intended to accelerate its footprint in protein- and peptide-based solutions across end markets.
Two platforms combined
Oobli has spent the past decade refining a fermentation process to produce sweet proteins that occur naturally in rare fruits and berries found near the equator. Its commercial portfolio covers Oubli Fruit, Serendipity Berry and Katemfe Fruit sweet proteins, known scientifically as brazzein, monellin and thaumatin, which Oobli describes as the first of their kind in the sugar-reduction category.
According to the company, sweet proteins are hundreds to thousands of times sweeter than sugar, bind directly to sweet taste receptors and are metabolized by the body as protein, delivering sweetness without gut disruption or blood sugar spikes. Oobli's ingredients hold FDA GRAS status as an ingredient and are FEMA GRAS-affirmed for use as a natural flavor.
Oobli's commercial portfolio is expected to be the first to benefit from the combined platform. With consumer awareness of metabolic health and sugar reduction growing, the companies see potential applications spanning sports and nutrition, dairy, beverages, chocolate, bakery and confectionery.
Executive comments
Kathy Fortmann, Amyris' chief executive officer, described Oobli as a commercial and technology platform that complements Amyris' own, and said the company is positioned to change how sweetness reaches the market. She said that combining Oobli's protein expertise with Amyris' strain engineering, manufacturing scale and commercial capabilities could broaden its work in food and beverage, personal care, flavor and fragrances, agriculture and beyond.
Fortmann added that biomanufactured solutions succeed when they align with consumer demand and market needs, and that Oobli's platform gives brands a way to address sweet taste, sugar reduction and clean label simultaneously.
Ali Wing, Oobli's chief executive officer, said the company has long believed there is a better way to deliver the sweet taste consumers want without trade-offs to health and the environment. She said joining Amyris provides the scale and resources to pursue Oobli's ambition of making sweet proteins a global standard in sweetness solutions.
Customer continuity
Amyris said all existing customer commitments and brand partnerships will continue to be honored without interruption as Oobli's portfolio expands within the company.
